academic.oup.com
Treat-to-target in SLE: is serology important? Results from an integrated analysis of five randomized clinical trials of belimumab
AbstractObjectives. DORIS remission, based on clinical activity, and lupus low disease activity state (LLDAS), which includes serological markers, are prot